Loading...
OTCM
RAPH
, Last price  
USD
Name

Raphael Pharmaceutical Inc

Chart & performance

D1W1MN
OTCM:RAPH chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
—
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
Net income
-1m
L-15.80%
-1,624,000-3,358,000-1,344,000-1,519,000-1,279,000
CFO
-210k
L-60.53%
-1,418,000-759,000-1,203,000-532,000-210,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Raphael Pharmaceutical Inc. operates as a biopharmaceutical firm, concentrating its efforts on discovering and clinically developing novel therapeutic solutions. These treatments primarily leverage cannabinoids and are designed to enhance patients' quality of life. Currently, the company's leading investigational drug candidate is being advanced for the management of rheumatoid arthritis. Furthermore, Raphael Pharma plans to broaden its pipeline to include more cannabinoid-based medicines aimed at various cancer types and other autoimmune conditions. The company's corporate headquarters are situated in Tel Aviv-Jaffa, Israel.

Key people

Emanuel Cohen
Chief Financial Officer, Treasurer, Secretary · since 2010
Director · since 2010
Guy Ofir
President, Chief Executive Officer, Director · since 2007
Director · since 2010
Elisha Yanay
Director · since 2010
URL
IPO date
Aug 23, 2022
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT